Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves

Summary

Agenus highlighted progress with its BOT/BAL immunotherapy combination in refractory MSS colorectal cancer, with the phase 3 BATMAN trial enrolling since April. The company's balance sheet improved to $35 million cash after a Zydus collaboration, and it is preparing potential U.S. accelerated approval and European conditional marketing authorization filings.

Market Impact

Positive clinical data and a strengthened balance sheet may improve investor sentiment toward Agenus, though the first overall survival readout is not expected until H2 2028, limiting near-term catalysts. Regulatory progress in the U.S. and Europe could create upside if accelerated approval is pursued.

Why It Matters

Agenus is advancing a novel immunotherapy combination in a difficult-to-treat cancer (MSS colorectal cancer) with limited treatment options, and an improved cash position reduces near-term dilution risk.

Key Points

• BOT/BAL is Agenus' lead candidate, with ~1,300 patients treated and a focus on refractory MSS colorectal cancer.
• Phase 3 BATMAN trial (BOT/BAL vs best supportive care) began enrolling in April 2026; first OS readout expected H2 2028.
• Cash improved from ~$3M (end 2025) to ~$35M (Q1 2026) after Zydus collaboration and ATM proceeds.
• Company preparing potential accelerated approval filing in U.S. and conditional marketing authorization in Europe.
• BOT/BAL available in France via compassionate access; also in select countries through named-patient programs.

Key Entities

Evidence

BOT/BAL remains Agenus’ main focus as the company advances botensilimab/balstilimab in hard-to-treat cancers, especially refractory MSS metastatic colorectal cancer.

Supports: BOT/BAL is the primary focus for Agenus.

The global phase 3 BATMAN trial is underway, comparing BOT/BAL with best supportive care in refractory MSS or pMMR metastatic colorectal cancer.

Supports: Phase 3 trial is ongoing.

In heavily pretreated MSS metastatic colorectal cancer patients without active liver metastases, Armen said BOT/BAL has demonstrated 42% two-year overall survival and median overall survival of about 21 months.

Supports: Positive efficacy data in key patient group.

Management said the program has treated about 1,300 patients and is now the lead candidate for phase 3 and regulatory development.

Supports: Extensive patient exposure and lead candidate status.